LEADER 05995nam 2201681z- 450 001 9910367566603321 005 20231214132829.0 010 $a3-03921-392-X 035 $a(CKB)4100000010106080 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/49693 035 $a(EXLCZ)994100000010106080 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHurdles for Phage Therapy (PT) to Become a Reality 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (484 p.) 311 $a3-03921-391-1 330 $aAlternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage?bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing. 517 $aHurdles for Phage Therapy 610 $aalginate 610 $aabortive infection 610 $abacterial resistance 610 $abacteriophages 610 $aATMP 610 $aMALDI-MS 610 $aadaptation 610 $aBacteriophage 610 $ahorizontal gene transfer 610 $aadaptive immunity 610 $aco-evolution 610 $aListeria ivanovii 610 $apersonalised medicines 610 $apH stability 610 $aphage-human host interaction 610 $avB_SauM-fRuSau02 610 $aantimicrobial resistance 610 $aphagodisinfection 610 $abiofilm 610 $acapsule depolymerase 610 $aanimal model 610 $aphage cocktails 610 $aEnterococcus 610 $acases report 610 $azoonosis 610 $aresistance 610 $amagistral formula 610 $aexperimental therapy 610 $aBelgium 610 $aphage therapy 610 $aE. faecalis 610 $anontraditional antibacterial 610 $aindustrial phage application 610 $aDemocratic Republic of the Congo 610 $aOrthoMCL 610 $aGermany 610 $ahigh-throughput sequencing 610 $aantimicrobial 610 $ainfection 610 $aantibiotic therapy 610 $aKayvirus 610 $aphages 610 $aTwortlikevirus 610 $abacterial disease 610 $ahuman host 610 $aPseudomonas aeruginosa 610 $aphage 610 $amultidrug-resistant bacteria 610 $abacterial infection 610 $aSalmonella Typhi 610 $arhamnopolysaccharide 610 $acompassionate use 610 $acrop production 610 $acompounding pharmacy 610 $aantimicrobial resistance (AMR) 610 $abest practices 610 $abacteriophage efficacy 610 $aphage sensitivity 610 $aantibiotic-resistance 610 $aantibiotic 610 $alysins 610 $aPTMP 610 $aEscherichia coli 610 $atyphoid fever 610 $apatent landscape 610 $aphage preparation 610 $ainnate immunity 610 $aanti-phage antibodies 610 $aimmunology 610 $aStaphylococcus aureus 610 $aglobal health 610 $aclinical trial 610 $aadsorption 610 $aBrussels 610 $aphage-resistance 610 $aGalleria mellonella 610 $ascience communication 610 $ahistory of science 610 $avirus-host interactions 610 $afoodborne illness 610 $aprophage 610 $aresistance management 610 $abiofilms 610 $aIND 610 $aimmunomodulation 610 $afrequency of resistance 610 $acapsule 610 $agastrointestinal tract 610 $aphage-host interactions 610 $adisinfection 610 $aproduction 610 $abacteriophage therapy 610 $abacteriophage 610 $aStaphylococcus 610 $amagistral preparation 610 $aextended-spectrum beta lactamases (ESBL) 610 $aViral proteins 610 $aantibiotic resistance 610 $agenomics 610 $aphage biocontrol 610 $atherapy 610 $atarget selection 610 $aviral genomes 610 $aevolution 610 $apharmaceutical paradigm shift 610 $apersonalized medicine 610 $apharmaceutical legislation 610 $afood safety 610 $aregulation 610 $avirulence 610 $adeveloping countries 610 $ainfectious disease 610 $aregulatory framework 610 $asustainable agriculture 610 $aKlebsiella pneumoniae 700 $aBru?ssow$b Harald$4auth$01331097 906 $aBOOK 912 $a9910367566603321 996 $aHurdles for Phage Therapy (PT) to Become a Reality$93040125 997 $aUNINA